Confronting the barriers to develop novel vaccines against brucellosis

dc.creatorOliveira, Sérgio Costa
dc.creatorGiambartolomei, Guillermo Hernan
dc.creatorCassataro, Juliana
dc.date.accessioned2019-01-07T16:58:45Z
dc.date.accessioned2022-10-15T12:21:06Z
dc.date.available2019-01-07T16:58:45Z
dc.date.available2022-10-15T12:21:06Z
dc.date.created2019-01-07T16:58:45Z
dc.date.issued2011-09
dc.identifierOliveira, Sérgio Costa; Giambartolomei, Guillermo Hernan; Cassataro, Juliana; Confronting the barriers to develop novel vaccines against brucellosis; Expert Reviews; Expert Review Of Vaccines; 10; 9; 9-2011; 1291-1305
dc.identifier1476-0584
dc.identifierhttp://hdl.handle.net/11336/67556
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4385356
dc.description.abstractBrucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in domestic animals and undulant fever, arthritis, endocarditis and meningitis in humans. Currently, there is no vaccine licensed for brucellosis in humans. Furthermore, control of brucellosis in the human population relies on the control of animal disease. Available animal vaccines may cause disease and in some cases have limited efficacy. This article discusses recent studies in the development of recombinant protein, DNA and live-attenuated vaccines against brucellosis. Furthermore, we call the attention of the scientific community, government and industry professionals to the fact that for these novel vaccine initiatives to become licensed products they need to be effective in natural hosts and bypass the regulatory barriers present in several countries. © 2011 Expert Reviews Ltd.
dc.languageeng
dc.publisherExpert Reviews
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1586/erv.11.110
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1586/erv.11.110?journalCode=ierv20
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectBRUCELLA ABORTUS
dc.subjectBRUCELLOSIS
dc.subjectDNA VACCINE
dc.subjectLIVE-ATTENUATED VACCINE
dc.subjectRECOMBINANT PROTEIN VACCINE
dc.subjectVACCINE
dc.titleConfronting the barriers to develop novel vaccines against brucellosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución